StockNews.com started coverage on shares of GlycoMimetics (NASDAQ:GLYC – Free Report) in a report published on Friday morning. The firm issued a sell rating on the biotechnology company’s stock.
GlycoMimetics Trading Up 1.6 %
NASDAQ:GLYC opened at $0.26 on Friday. GlycoMimetics has a 1 year low of $0.14 and a 1 year high of $3.18. The firm has a 50 day moving average of $0.27 and a 200-day moving average of $0.25.
GlycoMimetics (NASDAQ:GLYC – Get Free Report) last posted its earnings results on Thursday, February 13th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. On average, equities research analysts predict that GlycoMimetics will post -0.08 earnings per share for the current year.
Institutional Inflows and Outflows
GlycoMimetics Company Profile
GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.
Further Reading
- Five stocks we like better than GlycoMimetics
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- How to Build the Ultimate Everything ETF Portfolio
- How to Calculate Inflation Rate
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.